146 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
. We are investing a majority of our efforts and financial resources into the research and development of these programs. We anticipate initiating … combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority … , by the Company and the Purchasers who collectively have subscribed to purchase at least a majority in interest of the Securities, which majority must
8-K
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority
8-K
EX-10.1
bmpn7q
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-10.2
o4hz9g
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
vbpb u7nyc
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
hlvfql44
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
pgf rgik4zvq
6 Feb 24
Prospectus supplement
9:37pm
8-K
dd35d bizq2
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
EX-10.1
jz8p7xjvy2tpq9
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
EX-3.1
8b5x6c8
5 Feb 24
Entry into a Material Definitive Agreement
7:36am